FeesSafety
Pluang+

XRP, a major cryptocurrency, trades at €1.14 with a fixed supply and ongoing Ripple company influence.

Protocol Fundamentals
04 Nov 2026, 15:19 WIB
CryptoTicker
View Source
Neutral
XRP, a major cryptocurrency, trades at €1.14 with a fixed supply and ongoing Ripple company influence.

XRP is the native coin of the XRP Ledger, created in 2012 with a fixed supply of 100 billion coins and no mining. Ripple, the company behind XRP, holds a significant portion of the supply and uses XRP as a bridge currency for fast cross-border payments. The XRP Ledger uses a consensus protocol instead of mining, enabling quick transactions with minimal fees that are burned, slightly reducing total supply over time. The SEC lawsuit against Ripple, which ended in 2025, heavily influenced XRP's price for years, but regulatory clarity and new ETFs have since improved market access, especially in the US and EU. Investors in Germany should buy XRP through licensed exchanges and be aware of tax rules and technical details like destination tags and base reserves.

The story about XRP provides context for readers interested in cryptocurrency markets. For readers following major cryptocurrencies on Pluang, here is the market snapshot as of Nov 04, 2026 20:22 WIB: out of 50 priced major cryptocurrencies, 28 rose and 20 fell today. Notable movers include Basic Attention Token (BAT) with a price of Rp2.507 and a 1-day change of +9.21%, EOS.IO (EOS) at Rp12.649 with +8.13%, and Nano (XNO) at Rp5.951 with +3.42%.

More News

Good Life Meds must stop unproven health and personalization claims for compounded Tirzepatide+ products.

Good Life Meds must stop unproven health and personalization claims for compounded Tirzepatide+ products.

The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...

Market News
Bearish
26 minutes ago
Moleculin's Annamycin shows promising remission rates in AML trial, data to be presented at ASH 2026.

Moleculin's Annamycin shows promising remission rates in AML trial, data to be presented at ASH 2026.

Moleculin Biotech announced that interim results from its Phase 2/3 trial of Annamycin for relapsed or refractory acute myeloid leukemia (AML) will be presented at the 2026 ASH Annual Meeting. The trial showed remission rates of 43% and 36% in two An...

Company Fundamentals
Bullish
26 minutes ago
ANZ dental implants market to grow 5% CAGR, reaching $393M by 2033 driven by aging population and prosthetic demand

ANZ dental implants market to grow 5% CAGR, reaching $393M by 2033 driven by aging population and prosthetic demand

The Australia and New Zealand (ANZ) dental implants market, valued at $266 million in 2025, is projected to grow at a 5% CAGR to $393 million by 2033. Growth is driven by increasing demand for oral rehabilitation and prosthetic dentistry, especially ...

Market News
Bullish
26 minutes ago
New study shows Asgard's tech induces cancer-fighting structures in tumors, boosting therapy success across 7 cancer types.

New study shows Asgard's tech induces cancer-fighting structures in tumors, boosting therapy success across 7 cancer types.

Asgard Therapeutics published a study in Immunity demonstrating its technology can reprogram tumor cells into dendritic cells, inducing cancer-fighting tertiary lymphoid structures (imgTLSs) across seven tumor types. This tumor-agnostic approach led ...

Others
Bullish
26 minutes ago
Cap expands onchain credit marketplace to finance film production without tokenizing assets

Cap expands onchain credit marketplace to finance film production without tokenizing assets

Cap, an onchain credit marketplace, is expanding into film and media financing by providing funding for the upcoming film Wake. This deal uses advances against anticipated film production tax credits, showing how Cap's underwriting model supports spe...

Market News
Bullish
26 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App